IDH1 and cholangiocarcinoma: Interestingly, despite the high crossover rate in this trial, ivosidenib demonstrated good tolerability and did not cause a decline in QOL, while showing a significant improvement in overall survival compared to the placebo, thereby demonstrating the clinical efficacy of ivosidenib in patients with advanced CCA harboring IDH1 mutations.